Anti-Human HGFR/c-MET Bispecific Reference Antibody (Ecagitatug, RUO) (HY196226)

Name: Anti-Human HGFR/c-MET Bispecific Reference Antibody (Ecagitatug, RUO)
Brand: abinScience
SKU: HY196226
Price: 370 USD
Availability: InStock

Даташит Поделиться продуктом Копировать информацию

Цена(USD):

Спецификация:

100ug
1mg

Количество:

Свяжитесь с нами

Обзор
Изображения
Ссылки
Даташит
SDS

Обзор

Каталожный номер	HY196226
Описание	Anti-Human HGFR/c-MET Bispecific Reference Antibody (Ecagitatug, RUO) (HY196226) is a human monoclonal antibody detecting HGFR/c-MET.
Реактивность видов	Human
Применения	ELISA, FACS, Functional assay
Хозяинский вид	Human
Клоональность	Monoclonal
Изотип	IgG2, kappa
Цель	EC:2.7.10.1, HGF receptor, HGF/SF receptor, Hepatocyte growth factor receptor, MET, Proto-oncogene c-Met, SF receptor, Scatter factor receptor, Tyrosine-protein kinase Met
Уровень эндотоксинов	< 10 EU/mg
Чистота	>95% as determined by SDS-PAGE.
Очистка	Protein A/G purified from cell culture supernatant.
Номер доступа	P08581
Форма	Liquid
Буфер хранения	0.01M PBS pH 7.4 Пожалуйста, обратитесь к конкретной информации о буфере в печатной версии даташита или в индивидуальном сертификате качества (COA) для партии.
Устойчивость и хранение	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term from the date of receipt..
Альтернативные названия	CAS: 3076369-09-7
Фон	Hepatocyte growth factor receptor (MET/HGFR) is a ~155 kDa protein. Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to hepatocyte growth factor/HGF ligand. Regulates many physiological processes including proliferation, scattering, morphogenesis and survival. Ligand binding at the cell surface induces autophosphorylation of MET on its intracellular domain that provides docking sites for downstream signaling molecules. Following activation by ligand, interacts with the PI3-kinase subunit PIK3R1, PLCG1, SRC, GRB2, STAT3 or the adapter GAB1. Recruitment of these downstream effectors by MET leads to the activation of several signaling cascades including the RAS-ERK, PI3 kinase-AKT, or PLCgamma-PKC. MET is the therapeutic target of amivantamab (Rybrevant).
Примечание	For research use only.